Glaxo's Strategy For Drug Performance Units Is Showing Promise, Slaoui Says
This article was originally published in The Pink Sheet Daily
R&D Chairman Moncef Slaoui provides update on drug performance units one year out at Windhover's Pharmaceutical Strategic Alliance Conference.
You may also be interested in...
Not satisfied with its R&D experiments to date, GSK has taken its most radical step yet toward re-creating biotech within its walls: even smaller units complete with investment boards occupied by external VCs and CEOs and milestone-based funding and external VCs.
Planned units include five to 80 scientists, operate within the CEDDs program.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.